1YBetter than half the group
Rank 26 of 63 funds
Return +19.18%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 26No. 1 is SCBGENOME(E) +62.13%
SCB GLOBAL HEALTH CARE RMF
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
SCBRMGHC invests through the master fund Janus Henderson Global Life Sciences Fund 99.14%
This fundSCBRMGHC
The fund that actually investsJanus Henderson Global Life Sciences FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY9.53%
Johnson & Johnson JNJ7.71%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Janus Henderson fact sheet
Over the past year it beat half its group; over 5 years it returned +3.81% per year (Top 25% of the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +10.03% | +2.73% | +5.09% | +7.13% | +4.42% | +13.92% | +19.29% | +44.16% | +20.54% | +71.47% | +129.30% |
Largest drawdown in the selected period −28.27% Previous peak 12 Feb 2020 (NAV 12.8245) → Trough 23 Mar 2020 (NAV 9.1990) · Back to the previous peak on 23 Jun 2020, after 3 months
Currently −2.58% from the peak NAV of 19.9502 (19 Aug 2026)
Over 5 years, SCBRMGHC returned 0.23 per unit of volatility, ranking 3 of 33 funds · The highest is FP HCARE-A (0.43)
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียว (Feeder Fund) ได้แก่ Janus Henderson Global Life Sciences Fund (กองทุนหลัก) ชนิดหน่วยลงทุน (share class) I acc สกุลเงินดอลลาร์สหรัฐ (USD) กองทุนหลักบริหารโดย Henderson Management S.A. จดทะเบียนภายใต้กฎหมายของประเทศไอร์แลนด… Its largest holdings are หน่วยลงทุน JANUS HENDERSON GLOBAL LIFE SCIENCES FUND 99.14% (fact sheet 31 Aug 2026)
Risk level 7 of 8 (High risk). Since 6 Nov 2015, its NAV has fallen as much as −28.27% from its peak.
Actual total expense ratio (TER) 1.18% a year, against a ceiling of 2.89%. Management fee 1.07%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1,000 THB, subsequent purchases 1,000 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+5
SCBRMGHC is a retirement mutual fund (RMF). You can buy up to 30% of your assessable income, capped at 500,000 THB a year together with other retirement funds. You must hold it for at least 5 years and can sell only once you turn 55. Check the latest conditions with the Revenue Department before investing
Almost fully hedged. As of 31 Aug 2026, 99.36% of the value of its foreign investments was hedged
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Unitedhealth Group UNH4.23%
AstraZeneca AZN.L3.68%
Thermo Fisher TMO3.32%
Novartis NOVN2.71%
Roche ROG2.66%
argenx ARGX2.43%
Merck & MRK2.33%Eli Lilly and Co LLYDiabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
ABBVIE ABBVHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Novartis NOVNHospitals, medicines and medical equipment
Roche ROGHospitals, medicines and medical equipment
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Merck & MRKHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (99.14% as of 31 Aug 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
No. 1 is FP HCARE-A +6.61% per year
| +94.36% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.2 | +1.7 | −6.4 | +1.3 | +1.8 | +8.1 | −0.9 | +3.3 | −4.4 | +6.4 | −0.6 | · | +10.0* |
| 2025 | +5.4 | −0.4 | −4.8 | −0.9 | −6.0 | +1.8 | −1.1 | +5.5 | +2.3 | +8.3 | +8.9 | −0.4 | +18.8 |
| 2024 | +2.2 | +3.6 | +1.5 | −5.1 | +3.1 | +2.9 | +1.9 | +4.0 | −3.0 | −3.1 | −0.7 | −8.0 | −1.5 |
| 2023 | −0.2 | −4.1 | +1.9 | +3.6 | −2.7 | +2.8 | +0.3 | −1.7 | −4.1 | −7.0 | +6.8 | +7.0 | +1.5 |
| 2022 | −9.2 | +0.4 | +3.5 | −7.0 | −1.2 | −0.6 | +4.3 | −3.4 | −3.2 | +8.3 | +4.8 | −1.4 | −5.9 |